Cohort Study, Heart Failure
Conditions
Keywords
candesartan, heart failure, cohort study, France
Brief summary
The purpose of this study is to describe the way candesartan is used in heart failure treatment in France (treatment initiation and monitoring), treatment stops occurrence and reasons for and patients clinical evolution
Interventions
DRUGCandesartan
Oral tablets
Sponsors
Takeda
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
Exclusion criteria
* patients included in a clinical trial the last 30 days before consultation * patients unable to answer the questions for linguistic or cognitive reasons * patients who will be difficult to follow during the one year study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Profile of patients treated with candesartan for heart failure | At inclusion |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients taking correctly its treatment : indication, contraindication, drug titration, treatment monitoring | 6 and 12 months after |
| Percentage of patients stopping its treatment and reasons why | 12 months after |
| Percentage of hospitalisations due to heart failure and cardiovascular deaths | 12 months after |
Countries
France
Outcome results
None listed